Literature DB >> 12712057

Noninvasive delivery of inhaled nitric oxide therapy for late pulmonary hypertension in newborn infants with congenital diaphragmatic hernia.

John P Kinsella1, Thomas A Parker, D Dunbar Ivy, Steven H Abman.   

Abstract

OBJECTIVE: To determine the incidence of late pulmonary hypertension (late PH) in congenital diaphragmatic hernia (CDH) and whether prolonged treatment with noninvasive inhaled NO therapy delivered through a nasal cannula (NC) would sustain pulmonary vasodilation during a period of transition from mechanical ventilation to spontaneous breathing. STUDY
DESIGN: We collected data on all patients with a diagnosis of CDH admitted to the Children's Hospital, Denver, from January 1996 through December 2001. Patients who had suprasystemic pulmonary hypertension when inhaled NO was discontinued before extubation were treated with inhaled NO delivered with the nasal cannula.
RESULTS: Newborn infants (n = 47) with CDH were treated during this time period. Short-term (<3 months) and long-term (>1 year) survival was 85% and 75%, respectively; 30 newborn infants were treated with inhaled NO (64%). Inhaled NO was successfully discontinued in 16 patients before extubation, and 10 (21%) were treated with inhaled NO through NC after extubation because of pulmonary hypertension and marked hypoxemia when trials off inhaled NO were performed. Nasopharyngeal NO concentrations were 5.4 +/- 0.5 ppm and 2.4 +/- 0.4 ppm with inhaled NO measured proximally in the delivery device at 10 and 5 ppm, respectively.
CONCLUSIONS: Late PH occurs in a significant subset of newborn infants with CDH. Noninvasive inhaled NO treatment may reduce the duration of mechanical ventilation while safely treating late PH.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12712057     DOI: 10.1067/mpd.2003.140

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  14 in total

Review 1.  Imaging findings in fetal diaphragmatic abnormalities.

Authors:  Leonor Alamo; François Gudinchet; Reto Meuli
Journal:  Pediatr Radiol       Date:  2015-08-09

2.  Noninvasive inhaled nitric oxide does not prevent bronchopulmonary dysplasia in premature newborns.

Authors:  John P Kinsella; Gary R Cutter; Robin H Steinhorn; Leif D Nelin; William F Walsh; Neil N Finer; Steven H Abman
Journal:  J Pediatr       Date:  2014-07-22       Impact factor: 4.406

Review 3.  Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents.

Authors:  Nicolas F M Porta; Robin H Steinhorn
Journal:  Clin Perinatol       Date:  2012-03       Impact factor: 3.430

4.  Looking beyond PPHN: the unmet challenge of chronic progressive pulmonary hypertension in the newborn.

Authors:  Candice D Fike; Judy L Aschner
Journal:  Pulm Circ       Date:  2013-11-19       Impact factor: 3.017

5.  Trends in treatment and in-hospital mortality for neonates with congenital diaphragmatic hernia.

Authors:  J I Hagadorn; E A Brownell; K W Herbst; J M Trzaski; S Neff; B T Campbell
Journal:  J Perinatol       Date:  2015-05-07       Impact factor: 2.521

Review 6.  Pharmacotherapy for pulmonary hypertension.

Authors:  Robin H Steinhorn
Journal:  Pediatr Clin North Am       Date:  2012-08-26       Impact factor: 3.278

Review 7.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 8.  Inhaled NO in the experimental setting.

Authors:  Nicolas F M Porta; Robin H Steinhorn
Journal:  Early Hum Dev       Date:  2008-10-22       Impact factor: 2.079

Review 9.  Management of pulmonary hypertension in infants with congenital diaphragmatic hernia.

Authors:  J Gien; J P Kinsella
Journal:  J Perinatol       Date:  2016-06       Impact factor: 2.521

10.  Diagnosis and treatment of pulmonary hypertension in infancy.

Authors:  Robin H Steinhorn
Journal:  Early Hum Dev       Date:  2013-09-29       Impact factor: 2.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.